Cancers Treated:
Specializing In:
- Peritoneal surface malignancies
- HIPEC (Hyperthermic Intraperitoneal Chemotherapy)
Biography
As a surgical oncologist, I specialize in treating peritoneal surface malignancies, including conditions like appendiceal cancer, colorectal cancer with peritoneal metastasis, and mesothelioma. These patients often face a difficult prognosis and have significant concerns about their future and quality of life. My focus is on providing effective treatment strategies, including approaches like HIPEC (Hyperthermic Intraperitoneal Chemotherapy), with a commitment to achieving the best possible outcomes.
In addition, I am also experienced in the surgical management of melanoma and sarcoma. I also integrate advanced robotic surgery into my practice for various oncologic cases, leveraging its benefits for improved surgical outcomes and patient recovery.
Positions
Roswell Park Comprehensive Cancer Center
- Assistant Professor of Oncology
- Department of Surgical Oncology
Background
Education and Training
- 2009-2013 - MD - Robert Wood Johnson Medical School, New Brunswick, NJ
- 2009 - BS - Rutgers University, New Brunswick, NJ
Residency
- 2013-2020 - General Surgery Residency - University of Rochester, Rochester, NY
Fellowship
- 2020-2022 - Complex General Surgical Oncology Fellowship - Roswell Park Comprehensive Cancer Center, Buffalo, NY
- 2015-2017 - Research Fellow - Center of Tumor Immunology, University of Rochester, Rochester, NY
Board Certification
- General Surgery - American Board of Surgery
- Complex General Surgical Oncology - American Board of Surgery
Professional Memberships
- American College of Surgeons
- Society of Surgical Oncology
Professional Experience
- 2020-2022 - Surgical Oncology, Rochester Regional Health System, Rochester, NY
Publications
Patel A, Skitzki J. "Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials."; Journal of Surgical Oncology 125.1 (2022): 38-45. PMID 34897704
Patel A, Kane J. “Wide Resection of Extremity/Truncal Soft Tissue Sarcomas.” Surgical Clinics. 102, no.4, p 551-65 (2022). PMID 35952687
Patel A, Oba T, Kajihara R, Yokoi T, Abrams S, Ito F. “Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to anti-PDL1 Therapy.” Journal of Immunology (2021). PMID 34362833
Patel A, Oshi M, Yan L, Matsuyama R, Endo I, Takabe K. “The Unfolded Protein Response is Associated with Worse Survival in Hepatocellular Carcinoma.” Cancers 13, no. 17, p 4443 (2021). PMID 34503253
Nywening TM, Belt BA, Cullinan DR, Panni RZ, Han BJ, Sanford DE, Jacobs RC, Ye J, Patel A, Gillanders WE and Fields RC. “Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma.” Gut, pp.gutjnl (2017). PMID: 29196437